1. Home
  2. BCAB vs OPTX Comparison

BCAB vs OPTX Comparison

Compare BCAB & OPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • OPTX
  • Stock Information
  • Founded
  • BCAB 2007
  • OPTX 1981
  • Country
  • BCAB United States
  • OPTX United States
  • Employees
  • BCAB N/A
  • OPTX N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • OPTX Blank Checks
  • Sector
  • BCAB Health Care
  • OPTX Finance
  • Exchange
  • BCAB Nasdaq
  • OPTX Nasdaq
  • Market Cap
  • BCAB 91.4M
  • OPTX 41.8M
  • IPO Year
  • BCAB 2020
  • OPTX N/A
  • Fundamental
  • Price
  • BCAB $1.68
  • OPTX $1.30
  • Analyst Decision
  • BCAB Strong Buy
  • OPTX
  • Analyst Count
  • BCAB 3
  • OPTX 0
  • Target Price
  • BCAB $8.67
  • OPTX N/A
  • AVG Volume (30 Days)
  • BCAB 571.3K
  • OPTX 17.5K
  • Earning Date
  • BCAB 11-05-2024
  • OPTX 08-14-2024
  • Dividend Yield
  • BCAB N/A
  • OPTX N/A
  • EPS Growth
  • BCAB N/A
  • OPTX 81.79
  • EPS
  • BCAB N/A
  • OPTX 0.01
  • Revenue
  • BCAB N/A
  • OPTX $28,126,356.00
  • Revenue This Year
  • BCAB N/A
  • OPTX N/A
  • Revenue Next Year
  • BCAB N/A
  • OPTX N/A
  • P/E Ratio
  • BCAB N/A
  • OPTX $105.39
  • Revenue Growth
  • BCAB N/A
  • OPTX N/A
  • 52 Week Low
  • BCAB $1.14
  • OPTX $0.95
  • 52 Week High
  • BCAB $4.02
  • OPTX $19.50
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 45.55
  • OPTX 44.69
  • Support Level
  • BCAB $1.72
  • OPTX $1.12
  • Resistance Level
  • BCAB $1.85
  • OPTX $1.43
  • Average True Range (ATR)
  • BCAB 0.13
  • OPTX 0.09
  • MACD
  • BCAB -0.02
  • OPTX 0.02
  • Stochastic Oscillator
  • BCAB 10.34
  • OPTX 52.17

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About OPTX Syntec Optics Holdings Inc.

Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.

Share on Social Networks: